Browsing Cancer Biology by subject "KEYNOTE-048 Investigators"
Now showing items 1-1 of 1
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. BACKGROUND:Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response. METHODS:KEYNOTE-048 was a randomised, phase 3 ...